The Role of B Cells in Primary Progressive Multiple Sclerosis

The Role of B Cells in Primary Progressive Multiple Sclerosis

The success of ocrelizumab in reducing confirmed disability accumulation in primary progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as causal agents in the pathogenesis of PPMS. This review explores the possible mechanisms by which B cells contribute to disease p...

Full description

Bibliographic Details
Main Authors:	Jameson P. Holloman, Robert C. Axtell, Nancy L. Monson, Gregory F. Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Neurology
Subjects:	B cell multiple sclerosis immune pathogenesis inflammation primary progressive multiple sclerosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.680581/full

Similar Items

OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01)

Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
by: Katelijn M. Blok, et al.
Published: (2023-11-01)

APOE epsilon status in Hungarian patients with primary progressive multiple sclerosis
by: E Losonczi, et al.
Published: (2010-11-01)

Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis
by: Ya. V. Vlasov, et al.
Published: (2021-09-01)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
by: Crystal Watson, et al.
Published: (2023-09-01)

Deciphering Multiple Sclerosis Progression
by: Virginia Meca-Lallana, et al.
Published: (2021-04-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
by: Vermersch Patrick, et al.
Published: (2012-06-01)

Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases
by: Priyadarshi Prajjwal, et al.
Published: (2023-07-01)

Dual Role of B Cells in Multiple Sclerosis
by: Gaurav Kumar, et al.
Published: (2023-01-01)

Primary progressive multiple sclerosis in the Polish population
by: Waldemar Brola, et al.
Published: (2017-03-01)

Rehabilitation of patients with progressive forms of multiple sclerosis
by: S. A. Sivertseva, et al.
Published: (2022-08-01)

Changes in retinal structures as markers of multiple sclerosis progression
by: M. O. Poplyak, et al.
Published: (2021-12-01)

Consensus on early detection of disease progression in patients with multiple sclerosis
by: José E. Meca-Lallana, et al.
Published: (2022-07-01)

Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms
by: Ayache SS, et al.
Published: (2016-05-01)

Multiple sclerosis: current state
by: A. V. Peresedova, et al.
Published: (2017-02-01)

A case report of carbamazepine‐induced oropharyngeal dysphagia in a patient with primary progressive multiple sclerosis
by: Daniel Bishev, et al.
Published: (2023-05-01)

Emerging Role of Follicular T Helper Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
by: James L. Quinn, et al.
Published: (2018-10-01)

Multiple sclerosis: modern conception of pathogenesis and treatment
by: I. A. Zavalishin, et al.
Published: (2007-03-01)

Proteomics in Multiple Sclerosis: The Perspective of the Clinician
by: Dániel Sandi, et al.
Published: (2022-05-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)

Multiple sclerosis /
by: 546326 Dobson, Ruth, et al.
Published: (2013)

New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01)

Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial
by: Ethel Ciampi, et al.
Published: (2020-05-01)

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis
by: Jonathan A. Gernert, et al.
Published: (2023-08-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

Multiple sclerosis : recovery of function and neurorehabilitation /
by: Kesselring, Jurg, et al.
Published: (c201)

Rehabilitation treatment of multiple sclerosis
by: Haoyang Duan, et al.
Published: (2023-04-01)

Novel Drugs in a Pipeline for Progressive Multiple Sclerosis
by: Klaudia Sapko, et al.
Published: (2022-06-01)

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
by: Emily Kamma, et al.
Published: (2022-02-01)

Linear Modeling of Multiple Sclerosis and Its Subgroubs
by: Yeliz Karaca, et al.
Published: (2015-03-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

The Importance of Cerebellar Involvement in Identifying the Prognosis in Patients with Progressive Multiple Sclerosis
by: Egemen İdiman, et al.
Published: (2004-04-01)

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil
by: Vijayalakshmi Vasanthaprasad, et al.
Published: (2022-08-01)

Malignant multiple sclerosis: clinical and demographic prognostic factors
by: Fabrício Hampshire-Araújo, et al.

Advances in clinical diagnosis of secondary progressive multiple sclerosis
by: ZHANG Chao, GAO Xue
Published: (2022-12-01)

The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis
by: Saskia Räuber, et al.
Published: (2024-01-01)

Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
by: Ana Jerković, et al.
Published: (2022-07-01)

A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis
by: Rachael Kee, et al.
Published: (2022-10-01)

Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study
by: Cristina Agliardi, et al.
Published: (2023-01-01)